SAN JOSE, Calif., Dec. 16, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced the commercial launch of its Cchek™ Prostate Cancer
Confirmation test (Cchek™ PCC), the first test developed with the
Cchek™ artificial intelligence driven, flow cytometry based, liquid
biopsy technology platform.
The Cchek™ PCC test will be offered as a CLIA validated test
through Anixa's partner laboratory, ResearchDx. This test has
been independently validated by ResearchDx and is designed to
confirm the need for prostate biopsy, as a means to minimize
unnecessary invasive procedures and reduce healthcare costs
associated with traditional methods of prostate cancer diagnosis
and the associated adverse events.
Amit Kumar, Ph.D., Chief
Executive Officer of Anixa, stated, "This is a major milestone for
Anixa and our partner-based business model. From the start,
our goal with Cchek™ has been to develop an inexpensive blood test
that accurately detects the existence of cancer by measuring the
body's immune response."
Data shows that more than 90% of prostate biopsies performed in
the U.S. are negative, which indicates that over a million men
undergo unnecessary, painful and anxiety-provoking procedures every
year. The goal of Cchek™ PCC is to reduce the number of
unnecessary biopsies by between 40% and 50%, while still accurately
identifying those patients that require a biopsy to diagnose their
Dr. Kumar continued, "In the coming months, we expect to conduct
a number of activities to support the marketing of Cchek™ PCC,
including the development of marketing materials, education of key
opinion leaders in urology, and development of a reimbursement path
for the test. We expect Cchek™ PCC to be broadly available
throughout the U.S. by April
Cchek™ is an early cancer detection
technology, which measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a patient's
cancer status from a simple blood draw, eliminating the need for a
biopsy, which can be an expensive, painful and invasive procedure.
Further, conventional methods using current cancer screening tests
often lack accuracy and reliability. Anixa's orthogonal approach
using flow cytometry coupled with artificial intelligence provides
an alternative method with greater affordability, efficacy and
efficiency. To date, Anixa has successfully used Cchek™ to detect
the presence of 20 different cancers including lung, colon, breast
and prostate. The robust cancer detection performance of
Cchek™ makes it a platform from which multiple cancer diagnostic
tests may be developed.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not statements
of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
Johanna Bennett (Media)
View original content to download
SOURCE Anixa Biosciences, Inc.